ID   AL1A3_HUMAN             Reviewed;         512 AA.
AC   P47895; Q6NT64;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2004, sequence version 2.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=Aldehyde dehydrogenase family 1 member A3;
DE            EC=1.2.1.5 {ECO:0000269|PubMed:27759097};
DE   AltName: Full=Aldehyde dehydrogenase 6;
DE   AltName: Full=Retinaldehyde dehydrogenase 3;
DE            Short=RALDH-3;
DE            Short=RalDH3;
GN   Name=ALDH1A3; Synonyms=ALDH6 {ECO:0000303|PubMed:7698756};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Salivary gland;
RX   PubMed=7698756; DOI=10.1006/geno.1994.1624;
RA   Hsu L.C., Chang W.-C., Hiraoka L., Hsieh C.-L.;
RT   "Molecular cloning, genomic organization, and chromosomal localization
RT   of an additional human aldehyde dehydrogenase gene, ALDH6.";
RL   Genomics 24:333-341(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 2-15; 253-263; 407-421; 432-446 AND 488-501,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Dozynkiewicz M., Norman J.C.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [6]
RP   INVOLVEMENT IN MCOP8.
RX   PubMed=23591992; DOI=10.1093/hmg/ddt179;
RA   Yahyavi M., Abouzeid H., Gawdat G., de Preux A.S., Xiao T.,
RA   Bardakjian T., Schneider A., Choi A., Jorgenson E., Baier H.,
RA   El Sada M., Schorderet D.F., Slavotinek A.M.;
RT   "ALDH1A3 loss of function causes bilateral anophthalmia/microphthalmia
RT   and hypoplasia of the optic nerve and optic chiasm.";
RL   Hum. Mol. Genet. 22:3250-3258(2013).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   ALL-TRANS RETINOIC ACID, SUBUNIT, CATALYTIC ACTIVITY, ACTIVE SITE, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=27759097; DOI=10.1038/srep35710;
RA   Moretti A., Li J., Donini S., Sobol R.W., Rizzi M., Garavaglia S.;
RT   "Crystal structure of human aldehyde dehydrogenase 1A3 complexed with
RT   NAD(+) and retinoic acid.";
RL   Sci. Rep. 6:35710-35710(2016).
RN   [8]
RP   VARIANTS MCOP8 CYS-89 AND PRO-493, AND CHARACTERIZATION OF VARIANTS
RP   MCOP8 CYS-89 AND PRO-493.
RX   PubMed=23312594; DOI=10.1016/j.ajhg.2012.12.003;
RA   Fares-Taie L., Gerber S., Chassaing N., Clayton-Smith J., Hanein S.,
RA   Silva E., Serey M., Serre V., Gerard X., Baumann C., Plessis G.,
RA   Demeer B., Bretillon L., Bole C., Nitschke P., Munnich A., Lyonnet S.,
RA   Calvas P., Kaplan J., Ragge N., Rozet J.M.;
RT   "ALDH1A3 mutations cause recessive anophthalmia and microphthalmia.";
RL   Am. J. Hum. Genet. 92:265-270(2013).
RN   [9]
RP   VARIANTS MCOP8 VAL-145 AND PHE-369.
RX   PubMed=23646827; DOI=10.1111/cge.12184;
RA   Aldahmesh M.A., Khan A.O., Hijazi H., Alkuraya F.S.;
RT   "Mutations in ALDH1A3 cause Microphthalmia.";
RL   Clin. Genet. 84:128-131(2013).
RN   [10]
RP   VARIANT MCOP8 LYS-466.
RX   PubMed=24568872; DOI=10.1136/bjophthalmol-2013-304058;
RA   Semerci C.N., Kalay E., Yildirim C., Dincer T., Olmez A., Toraman B.,
RA   Kocyigit A., Bulgu Y., Okur V., Satiroglu-Tufan L., Akarsu N.A.;
RT   "Novel splice-site and missense mutations in the ALDH1A3 gene
RT   underlying autosomal recessive anophthalmia/microphthalmia.";
RL   Br. J. Ophthalmol. 98:832-840(2014).
RN   [11]
RP   VARIANT MCOP8 TYR-174.
RX   PubMed=24024553; DOI=10.1111/cge.12277;
RA   Roos L., Fang M., Dali C., Jensen H., Christoffersen N., Wu B.,
RA   Zhang J., Xu R., Harris P., Xu X., Groenskov K., Tuemer Z.;
RT   "A homozygous mutation in a consanguineous family consolidates the
RT   role of ALDH1A3 in autosomal recessive microphthalmia.";
RL   Clin. Genet. 86:276-281(2014).
RN   [12]
RP   VARIANT MCOP8 MET-71.
RX   PubMed=23881059; DOI=10.1038/ejhg.2013.157;
RA   Mory A., Ruiz F.X., Dagan E., Yakovtseva E.A., Kurolap A., Pares X.,
RA   Farres J., Gershoni-Baruch R.;
RT   "A missense mutation in ALDH1A3 causes isolated
RT   microphthalmia/anophthalmia in nine individuals from an inbred Muslim
RT   kindred.";
RL   Eur. J. Hum. Genet. 22:419-422(2014).
RN   [13]
RP   VARIANTS MCOP8 ARG-355; ARG-382 AND LYS-411.
RX   PubMed=24777706; DOI=10.1002/humu.22580;
RA   Abouzeid H., Favez T., Schmid A., Agosti C., Youssef M., Marzouk I.,
RA   El Shakankiry N., Bayoumi N., Munier F.L., Schorderet D.F.;
RT   "Mutations in ALDH1A3 represent a frequent cause of
RT   microphthalmia/anophthalmia in consanguineous families.";
RL   Hum. Mutat. 35:949-953(2014).
CC   -!- FUNCTION: NAD-dependent aldehyde dehydrogenase that catalyzes the
CC       formation of retinoic acid (PubMed:27759097). Has high activity
CC       with all-trans retinal, and has much lower in vitro activity with
CC       acetaldehyde (PubMed:27759097). Required for the biosynthesis of
CC       normal levels of retinoic acid in the embryonic ocular and nasal
CC       regions; retinoic acid is required for normal embryonic
CC       development of the eye and the nasal region (By similarity).
CC       {ECO:0000250|UniProtKB:Q9JHW9, ECO:0000269|PubMed:27759097}.
CC   -!- CATALYTIC ACTIVITY: An aldehyde + NAD(P)(+) + H(2)O = a
CC       carboxylate + NAD(P)H. {ECO:0000269|PubMed:27759097}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=9.3 uM for all-trans retinal {ECO:0000269|PubMed:27759097};
CC         KM=4.8 uM for NAD {ECO:0000269|PubMed:27759097};
CC         KM=2.4 mM for acetaldehyde {ECO:0000269|PubMed:27759097};
CC   -!- PATHWAY: Cofactor metabolism; retinol metabolism.
CC       {ECO:0000269|PubMed:27759097}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:27759097}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9JHW9}.
CC   -!- TISSUE SPECIFICITY: Expressed at low levels in many tissues and at
CC       higher levels in salivary gland, stomach, and kidney.
CC       {ECO:0000269|PubMed:7698756}.
CC   -!- DISEASE: Microphthalmia, isolated, 8 (MCOP8) [MIM:615113]: A
CC       disorder of eye formation, ranging from small size of a single eye
CC       to complete bilateral absence of ocular tissues. Ocular
CC       abnormalities like opacities of the cornea and lens, scaring of
CC       the retina and choroid, and other abnormalities may also be
CC       present. {ECO:0000269|PubMed:23312594,
CC       ECO:0000269|PubMed:23591992, ECO:0000269|PubMed:23646827,
CC       ECO:0000269|PubMed:23881059, ECO:0000269|PubMed:24024553,
CC       ECO:0000269|PubMed:24568872, ECO:0000269|PubMed:24777706}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the aldehyde dehydrogenase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U07919; AAA79036.1; -; mRNA.
DR   EMBL; BC069274; AAH69274.1; -; mRNA.
DR   CCDS; CCDS10389.1; -.
DR   PIR; A55684; A55684.
DR   RefSeq; NP_000684.2; NM_000693.3.
DR   RefSeq; NP_001280744.1; NM_001293815.1.
DR   UniGene; Hs.459538; -.
DR   UniGene; Hs.612155; -.
DR   PDB; 5FHZ; X-ray; 2.90 A; A/B/C/D/E/F/G/H=1-512.
DR   PDBsum; 5FHZ; -.
DR   ProteinModelPortal; P47895; -.
DR   SMR; P47895; -.
DR   BioGrid; 106722; 8.
DR   STRING; 9606.ENSP00000332256; -.
DR   BindingDB; P47895; -.
DR   ChEMBL; CHEMBL3579; -.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00162; Vitamin A.
DR   iPTMnet; P47895; -.
DR   PhosphoSitePlus; P47895; -.
DR   SwissPalm; P47895; -.
DR   BioMuta; ALDH1A3; -.
DR   DMDM; 52788258; -.
DR   EPD; P47895; -.
DR   MaxQB; P47895; -.
DR   PaxDb; P47895; -.
DR   PeptideAtlas; P47895; -.
DR   PRIDE; P47895; -.
DR   DNASU; 220; -.
DR   Ensembl; ENST00000329841; ENSP00000332256; ENSG00000184254.
DR   GeneID; 220; -.
DR   KEGG; hsa:220; -.
DR   UCSC; uc002bwn.5; human.
DR   CTD; 220; -.
DR   DisGeNET; 220; -.
DR   GeneCards; ALDH1A3; -.
DR   H-InvDB; HIX0026851; -.
DR   HGNC; HGNC:409; ALDH1A3.
DR   HPA; HPA046271; -.
DR   HPA; HPA064749; -.
DR   MalaCards; ALDH1A3; -.
DR   MIM; 600463; gene.
DR   MIM; 615113; phenotype.
DR   neXtProt; NX_P47895; -.
DR   OpenTargets; ENSG00000184254; -.
DR   Orphanet; 2542; Isolated anophthalmia - microphthalmia.
DR   PharmGKB; PA24694; -.
DR   eggNOG; KOG2450; Eukaryota.
DR   eggNOG; COG1012; LUCA.
DR   GeneTree; ENSGT00760000118999; -.
DR   HOGENOM; HOG000271505; -.
DR   HOVERGEN; HBG000097; -.
DR   InParanoid; P47895; -.
DR   KO; K00129; -.
DR   OMA; RIYADAR; -.
DR   OrthoDB; EOG091G05E8; -.
DR   PhylomeDB; P47895; -.
DR   TreeFam; TF300455; -.
DR   BioCyc; MetaCyc:HS00013-MONOMER; -.
DR   BRENDA; 1.2.1.5; 2681.
DR   Reactome; R-HSA-5365859; RA biosynthesis pathway.
DR   UniPathway; UPA00912; -.
DR   ChiTaRS; ALDH1A3; human.
DR   GeneWiki; ALDH1A3; -.
DR   GenomeRNAi; 220; -.
DR   PRO; PR:P47895; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000184254; -.
DR   CleanEx; HS_ALDH1A3; -.
DR   ExpressionAtlas; P47895; baseline and differential.
DR   Genevisible; P47895; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0004029; F:aldehyde dehydrogenase (NAD) activity; IBA:GO_Central.
DR   GO; GO:0004030; F:aldehyde dehydrogenase [NAD(P)+] activity; IDA:UniProtKB.
DR   GO; GO:0070403; F:NAD+ binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0001758; F:retinal dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0070324; F:thyroid hormone binding; IEA:Ensembl.
DR   GO; GO:0031076; P:embryonic camera-type eye development; ISS:UniProtKB.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0070384; P:Harderian gland development; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0021768; P:nucleus accumbens development; IEA:Ensembl.
DR   GO; GO:0060166; P:olfactory pit development; IEA:Ensembl.
DR   GO; GO:0002072; P:optic cup morphogenesis involved in camera-type eye development; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:0042574; P:retinal metabolic process; IDA:UniProtKB.
DR   GO; GO:0002138; P:retinoic acid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0042573; P:retinoic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0042572; P:retinol metabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0060013; P:righting reflex; IEA:Ensembl.
DR   Gene3D; 3.40.605.10; -; 1.
DR   InterPro; IPR016161; Ald_DH/histidinol_DH.
DR   InterPro; IPR016160; Ald_DH_CS_CYS.
DR   InterPro; IPR029510; Ald_DH_CS_GLU.
DR   InterPro; IPR016162; Ald_DH_N.
DR   InterPro; IPR015590; Aldehyde_DH_dom.
DR   Pfam; PF00171; Aldedh; 1.
DR   SUPFAM; SSF53720; SSF53720; 1.
DR   PROSITE; PS00070; ALDEHYDE_DEHYDR_CYS; 1.
DR   PROSITE; PS00687; ALDEHYDE_DEHYDR_GLU; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Microphthalmia; NAD;
KW   Oxidoreductase; Polymorphism; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.3}.
FT   CHAIN         2    512       Aldehyde dehydrogenase family 1 member
FT                                A3.
FT                                /FTId=PRO_0000056478.
FT   NP_BIND     257    262       NAD. {ECO:0000244|PDB:5FHZ,
FT                                ECO:0000269|PubMed:27759097}.
FT   ACT_SITE    280    280       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10007, ECO:0000255|PROSITE-
FT                                ProRule:PRU10008,
FT                                ECO:0000305|PubMed:27759097}.
FT   ACT_SITE    314    314       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10007, ECO:0000255|PROSITE-
FT                                ProRule:PRU10008}.
FT   BINDING     204    204       NAD. {ECO:0000244|PDB:5FHZ,
FT                                ECO:0000269|PubMed:27759097}.
FT   BINDING     207    207       NAD. {ECO:0000244|PDB:5FHZ,
FT                                ECO:0000269|PubMed:27759097}.
FT   BINDING     361    361       NAD. {ECO:0000244|PDB:5FHZ,
FT                                ECO:0000269|PubMed:27759097}.
FT   BINDING     411    411       NAD. {ECO:0000244|PDB:5FHZ,
FT                                ECO:0000269|PubMed:27759097}.
FT   SITE        181    181       Transition state stabilizer.
FT                                {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.3}.
FT   VARIANT      71     71       V -> M (in MCOP8; dbSNP:rs386834230).
FT                                {ECO:0000269|PubMed:23881059}.
FT                                /FTId=VAR_072332.
FT   VARIANT      89     89       R -> C (in MCOP8; does not affect ALDH1A3
FT                                expression; results in strongly reduced
FT                                protein levels; dbSNP:rs397514652).
FT                                {ECO:0000269|PubMed:23312594}.
FT                                /FTId=VAR_069322.
FT   VARIANT     145    145       A -> V (in MCOP8; dbSNP:rs754619607).
FT                                {ECO:0000269|PubMed:23646827}.
FT                                /FTId=VAR_069323.
FT   VARIANT     174    174       C -> Y (in MCOP8).
FT                                {ECO:0000269|PubMed:24024553}.
FT                                /FTId=VAR_072333.
FT   VARIANT     355    355       P -> R (in MCOP8).
FT                                {ECO:0000269|PubMed:24777706}.
FT                                /FTId=VAR_072334.
FT   VARIANT     369    369       I -> F (in MCOP8).
FT                                {ECO:0000269|PubMed:23646827}.
FT                                /FTId=VAR_069324.
FT   VARIANT     382    382       G -> R (in MCOP8).
FT                                {ECO:0000269|PubMed:24777706}.
FT                                /FTId=VAR_072335.
FT   VARIANT     386    386       M -> V (in dbSNP:rs3803430).
FT                                /FTId=VAR_019706.
FT   VARIANT     411    411       E -> K (in MCOP8).
FT                                {ECO:0000269|PubMed:24777706}.
FT                                /FTId=VAR_072336.
FT   VARIANT     466    466       N -> K (in MCOP8).
FT                                {ECO:0000269|PubMed:24568872}.
FT                                /FTId=VAR_072337.
FT   VARIANT     493    493       A -> P (in MCOP8; does not affect ALDH1A3
FT                                expression; results in strongly reduced
FT                                protein levels; dbSNP:rs397514653).
FT                                {ECO:0000269|PubMed:23312594}.
FT                                /FTId=VAR_069325.
FT   CONFLICT     15     15       R -> G (in Ref. 1; AAA79036).
FT                                {ECO:0000305}.
FT   STRAND       33     36       {ECO:0000244|PDB:5FHZ}.
FT   STRAND       39     41       {ECO:0000244|PDB:5FHZ}.
FT   STRAND       48     52       {ECO:0000244|PDB:5FHZ}.
FT   TURN         54     56       {ECO:0000244|PDB:5FHZ}.
FT   STRAND       58     64       {ECO:0000244|PDB:5FHZ}.
FT   HELIX        68     82       {ECO:0000244|PDB:5FHZ}.
FT   HELIX        87     90       {ECO:0000244|PDB:5FHZ}.
FT   HELIX        93    109       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       111    122       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       126    131       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       133    145       {ECO:0000244|PDB:5FHZ}.
FT   TURN        146    149       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      153    156       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      162    170       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      172    177       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      180    182       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       185    196       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      200    204       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       211    222       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      229    232       {ECO:0000244|PDB:5FHZ}.
FT   TURN        237    239       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       240    245       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      252    257       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       259    272       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      276    280       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      285    289       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       295    307       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       308    311       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      317    323       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       324    340       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      346    348       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       359    374       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      378    381       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      384    386       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      396    400       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       406    408       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      414    423       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       425    433       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      435    444       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       448    457       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      461    466       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      484    486       {ECO:0000244|PDB:5FHZ}.
FT   HELIX       491    495       {ECO:0000244|PDB:5FHZ}.
FT   STRAND      498    506       {ECO:0000244|PDB:5FHZ}.
SQ   SEQUENCE   512 AA;  56108 MW;  1BFCF4F56F0FE89A CRC64;
     MATANGAVEN GQPDRKPPAL PRPIRNLEVK FTKIFINNEW HESKSGKKFA TCNPSTREQI
     CEVEEGDKPD VDKAVEAAQV AFQRGSPWRR LDALSRGRLL HQLADLVERD RATLAALETM
     DTGKPFLHAF FIDLEGCIRT LRYFAGWADK IQGKTIPTDD NVVCFTRHEP IGVCGAITPW
     NFPLLMLVWK LAPALCCGNT MVLKPAEQTP LTALYLGSLI KEAGFPPGVV NIVPGFGPTV
     GAAISSHPQI NKIAFTGSTE VGKLVKEAAS RSNLKRVTLE LGGKNPCIVC ADADLDLAVE
     CAHQGVFFNQ GQCCTAASRV FVEEQVYSEF VRRSVEYAKK RPVGDPFDVK TEQGPQIDQK
     QFDKILELIE SGKKEGAKLE CGGSAMEDKG LFIKPTVFSE VTDNMRIAKE EIFGPVQPIL
     KFKSIEEVIK RANSTDYGLT AAVFTKNLDK ALKLASALES GTVWINCYNA LYAQAPFGGF
     KMSGNGRELG EYALAEYTEV KTVTIKLGDK NP
//
